Today’s the day! Our 2022 Light The Night season has officially kicked off. Drop a 🎉 if you’ll be joining us on a walk this season. 🙌

Our Takeda Resource Group (TRG), IMPACTO, empowers our #LatinX employees through professional growth and development, networking opportunities, and provides a platform to raise awareness of health inequities. #HispanicHeritageMonth

Teams accomplish more than individuals. Our deep in-house expertise is complemented by a network of symbiotic partnerships that optimize our ability to research, develop and deliver cutting-edge #oncology therapies for those with #cancer.

Frank Campana, MD, Executive Medical Director, Clinical Science recently joined the The Galien Foundation's Best Rare / Orphan Drug webinar to speak about our innovation story around Hodgkin lymphoma. Watch the webinar:

Access to and awareness of patient resources are critical in closing the #cancer care gap. Please join us ahead of #LCAM and #LCS_Day2022 in raising awareness of the lifesaving impact of #LungCancer screening. Find a screening center near you: bit.ly/3VOjrgy #lcsm

We’re proud to be a National Sponsor of The Leukemia & Lymphoma Society’s Light The Night Walk to bring light to the darkness of #cancer. Last week, we raised awareness and funds for those affected by blood cancer and support life-saving cancer research, gathering at the Boston Common to #LightTheNight.

Focusing on increasing diversity and reducing disparities in #ClinicalTrials is key to improving patient outcomes. Hear more from Liz Lewis, Head, Global Patient Value, Policy and Access. #HealthEquity

Join our own Dion Warren, Head, U.S. Oncology Business Unit, in a fireside chat with @FamilyReach's Carla Tardif at AtlanticLIVE's #PeopleVCancer next week to learn more about financial toxicity, a debilitating side effect of cancer.

Join Lisa Cruz, Global and US NSCLC Patient Advocacy and Engagements, at @GrytHealth’s #GlobalVirtualCancerConference as she co-moderates a panel discussing takeaways from our Health Equity in Lung Cancer Roundtable. #GVCC22 globalvirtualcancerconference.com/register/

Non-small cell lung cancer (#NSCLC) is the most common type of #LungCancer, accounting for 85% of lung cancer diagnoses. This #LungCancerAwarenessMonth, learn how identifying NSCLC mutations can help physicians pinpoint the most effective treatments for patients. #lcsm #LCAM

Join us at #ISPOREurope where our own Luis Hernandez, Head, Global Health Economics, Global Patient Value, Policy & Access, will convene with panelists to discuss #RWD quality vs. locality and how we can help deliver medicines to patients faster. #RWE

Life-changing treatments cannot make a difference if they do not reach those who need them. Liz Lewis, Head, Global Patient Value, Policy and Access, shares her thoughts on how to #CloseTheCareGap in cancer care. #HealthEquity #ISPOREurope

SPONSORED CONTENT: Family Reach’s Carla Tardif speaks to Takeda Oncology’s Dion Warren about the financial impacts of cancer treatment on families, how she started working to address them, & how to get involved. Watch this #PeopleVCancer Underwriter Session produced by Takeda

Earlier today, our own Dion Warren conducted a fireside chat with Carla Tardif, @FamilyReach CEO, at the AtlanticLIVE's #PeoplevCancer on financial toxicity. They discussed the financial costs associated with #cancer and how we're working to lessen the burden for patients.

Join us at the Economist Impact events #WorldCancerSeriesEurope, where our own Philippe Jacquot, VP & Country Manager, Oncology, and Stefanie Granado, Head of Oncology, EUCAN, will be participating in discussions on real-world data and digital transformation in #oncology.

This #KNOWvember, along with LUNGevity Foundation, we want to encourage all lung cancer patients to be fully informed about biomarker testing. Learn more about how to #KnowYourBiomarker for #NSCLC at noonemissed.org #IYKYK #LCAM #NoOneMissed

This #LungCancerAwarenessMonth, we gathered in Cambridge, MA for a white ribbon making event featuring the White Ribbon Project. Attendees heard from Dave Bjork of The White Ribbon Project™ and helped assemble white ribbons to drive awareness and change perceptions of #LungCancer. #LCAM

#News: Today, we announced that our Phase 3 trial for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia met its primary endpoint. Learn more:

How is next-generation sequencing (#NGS) revolutionizing the treatment of rare lung cancers? Our own Christine Ward joined Geoff Oxnard of Foundation Medicine to address this question in an episode of the Genetics Podcast. Listen below.